Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Erelzi

- PMLiVE

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

Detailed results from the NAVIGATOR trial presented at virtual AAAAI meeting

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

- PMLiVE

Rare genetic diseases – what’s in store for 2021?

Why personalised medicine based on our own genomes is the future of healthcare

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

- PMLiVE

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress

- PMLiVE

Amgen aims for first KRAS inhibitor approval in the US

Sotorasib is a potential treatment for advanced KRAS G12C-mutated NSCLC

- PMLiVE

Novartis receives FDA breakthrough therapy designation for rare disease med

The Swiss pharma company is eyeing approval in PNH and C3G indications

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links